2020
Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology 2020, 128: 417-424. PMID: 32781110, DOI: 10.1016/j.ophtha.2020.07.062.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsBevacizumabCerebrovascular DisordersDrug-Related Side Effects and Adverse ReactionsFemaleHemorrhageHospitalizationHumansIntravitreal InjectionsMaleMyocardial InfarctionRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal DiseasesRetrospective StudiesRisk AssessmentVascular Endothelial Growth Factor AConceptsNeovascular age-related macular degenerationRetinal venous occlusive diseaseDiabetic retinal diseaseSystemic serious adverse eventsAnti-VEGF injectionsAnti-VEGF agentsMajor bleedingAcute myocardial infarctionCause hospitalizationCerebrovascular diseaseRoutine clinical practiceMyocardial infarctionIntravitreal bevacizumabTreatment initiationAdverse eventsPropensity score-weighted Cox proportional hazards modelClinical practiceLarge U.S. administrative claims databaseRisk of MICox proportional hazards modelU.S. administrative claims databaseAge-related macular degenerationRisk-adjusted effectSystemic safety profileRetrospective cohort study
2019
Education level and outcomes after acute myocardial infarction in China
Huo X, Khera R, Zhang L, Herrin J, Bai X, Wang Q, Lu Y, Nasir K, Hu S, Li J, Li X, Zheng X, Masoudi FA, Spertus JA, Krumholz HM, Jiang L. Education level and outcomes after acute myocardial infarction in China. Heart 2019, 105: 946. PMID: 30661037, PMCID: PMC6582708, DOI: 10.1136/heartjnl-2018-313752.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsLow educational attainmentAcute myocardial infarction (AMI) outcomesAdverse cardiovascular eventsFuture healthcare interventionsMyocardial infarction outcomesCardiovascular risk factorsRisk-adjusted analysisAcute myocardial infarctionMedian participant ageCardiovascular eventsCause mortalityAdverse eventsConsecutive patientsAMI outcomesChina PatientUnadjusted analysesMyocardial infarctionRisk factorsChinese cohortHigh riskEducational attainmentEducational attainment groupsHealthcare interventionsPatients
2018
Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice. Ophthalmology 2018, 126: 1007-1015. PMID: 30292542, DOI: 10.1016/j.ophtha.2018.09.040.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaRoutine clinical practiceSystemic serious adverse eventsMacular laserMajor bleedingCerebrovascular diseaseMyocardial infarctionClinical practiceCause hospitalizationAdverse eventsHazard ratioIntravitreal corticosteroidsAnti-VEGFMacular edemaDME treatmentTreatment of DMEIntravitreal anti-VEGF therapyCox proportional hazards regressionAnti-VEGF pharmacotherapySystemic safety profileCorticosteroid-treated patientsRetrospective cohort studySerious adverse eventsSystemic adverse eventsMacular laser photocoagulation
2010
Telemonitoring in Patients with Heart Failure
Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, Phillips CO, Hodshon BV, Cooper LS, Krumholz HM. Telemonitoring in Patients with Heart Failure. New England Journal Of Medicine 2010, 363: 2301-2309. PMID: 21080835, PMCID: PMC3237394, DOI: 10.1056/nejmoa1010029.Peer-Reviewed Original ResearchConceptsPrimary end pointUsual care groupSecondary end pointsHeart failureEnd pointHeart failure outcomesNumber of hospitalizationsTelephone-based interactive voice response systemUsual careAdverse eventsPatient's clinicianMedian ageCare groupLarge trialsInteractive voice response systemPatientsSmall studyVoice response systemNumber of daysHospitalizationReadmissionTelemonitoringSignificant differencesCliniciansDeath